Literature DB >> 4722038

Further evidence for a central hypotensive action of alpha-methyldopa in both the rat and cat.

L Finch, G Haeusler.   

Abstract

1. alpha-Methyldopa (300 mg/kg i.p.) produced a fall in blood pressure in conscious genetic hypertensive rats. Pretreatment with intraventricular 6-hydroxydopamine prevented this hypotensive effect of alpha-methyldopa, whilst intravenous 6-hydroxydopamine reduced but did not prevent the hypotension.2. The hypotensive effect of alpha-methyldopa was prevented or reversed by intraventricular injection of phentolamine (200 mug/rat).3. Pressor responses obtained by stimulation of the entire sympathetic outflow in the Gillespie & Muir preparation, were unaffected by pretreatment with alpha-methyldopa (300 mg/kg i.p.).4. Vasoconstrictor responses to periarterial nerve stimulation of the isolated renal artery preparation of the rat were markedly reduced by pretreatment with alpha-methyldopa. Furthermore, alpha-methylnoradrenaline was found to have one-eighth the vasoconstrictor potency of noradrenaline in this particular artery preparation.5. Pressor responses obtained by stimulation of the posterior hypothalamus or midbrain reticular formation in the rat anaesthetized with urethane were markedly reduced by pretreatment with alpha-methyldopa. FLA-63, a selective dopamine-beta-hydroxylase inhibitor, prevented the reduction of the pressor responses to hypothalamic stimulation produced by alpha-methyldopa.6. Stimulation of the posterior hypothalamus in the anaesthetized cat caused both an increase in sympathetic nerve activity and a rise in blood pressure. These responses were markedly reduced 3-4 h after the injection of alpha-methyldopa (100 mg/kg i.v.).7. These results strongly suggest that the central actions of alpha-methyldopa are important for its hypotensive effect, although a possible peripheral effect cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4722038      PMCID: PMC1776563          DOI: 10.1111/j.1476-5381.1973.tb08319.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  36 in total

1.  Permanent cannulation of aorta and vena cava in rats and ground squirrels.

Authors:  V POPOVIC; P POPOVIC
Journal:  J Appl Physiol       Date:  1960-07       Impact factor: 3.531

2.  [On the mechanism of action of a new antihypertensive substance with imidazoline structure].

Authors:  W Kobinger
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1967

3.  Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-Hydroxydopamine.

Authors:  H Thoenen; J P Tranzer
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1968

4.  Central hypotensive effect of alpha-methyldopa.

Authors:  M Henning; P A van Zwieten
Journal:  J Pharm Pharmacol       Date:  1968-06       Impact factor: 3.765

5.  Adrenergic nerve function in the anaesthetized rat after treatment with a-methyldopa.

Authors:  M Henning; L Svensson
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1968

6.  Measurement of blood pressure in unanaesthetized rats and mice.

Authors:  M Gerold; H Tschirky
Journal:  Arzneimittelforschung       Date:  1968-10

7.  Adrenergic transmitter changes and response to sympathetic nerve stimulation after differing pretreatment with alpha-methyldopa.

Authors:  W Haefely; A Hürlimann; H Thoenen
Journal:  Br J Pharmacol Chemother       Date:  1967-09

8.  Construction and implantation of a permanent cannula for making injections into the lateral ventricle of the rat brain.

Authors:  J F Hayden; L R Johnson; R P Maickel
Journal:  Life Sci       Date:  1966-08       Impact factor: 5.037

9.  Pharmacological modifications of sympathetic responses elicited by hypothalamic stimulation in the rat.

Authors:  C Morpurgo
Journal:  Br J Pharmacol       Date:  1968-11       Impact factor: 8.739

10.  Localization of the hypotenisve effect of 2-(2-6-dichlorophenylamino)-2-imidazoline hydrochloride (St 155, Catapresan).

Authors:  H Schmitt; H Schmitt
Journal:  Eur J Pharmacol       Date:  1969-04       Impact factor: 4.432

View more
  19 in total

1.  Proceedings: A centrally-acting antihypertensive agent R28935, a pimozide analogue, not acting via alpha-adrenergic neurones.

Authors:  L Finch
Journal:  Br J Pharmacol       Date:  1975-10       Impact factor: 8.739

2.  Proceedings: Hypotensive action of alpha-methyldopamine.

Authors:  L Finch; A Hersom; P Hicks
Journal:  Br J Pharmacol       Date:  1975-06       Impact factor: 8.739

3.  Problems with Beta Adrenergic Blocking Drugs and other Antihypertensive Drugs.

Authors:  B N Prichard
Journal:  Proc R Soc Med       Date:  1977

4.  On the role of alpha-methyldopamine in the antihypertensive effect of alpha-methyldopa.

Authors:  P Waldmeier; P R Hedwal; L Maître
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1975       Impact factor: 3.000

Review 5.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

6.  Cardiovascular responses to centrally administered adrenaline in spontaneous hypertensive rats [proceedings].

Authors:  K R Borkowski; L Finch
Journal:  Br J Pharmacol       Date:  1977-09       Impact factor: 8.739

Review 7.  Central nervous system mechanisms in blood pressure control.

Authors:  A D Struthers; C T Dollery
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Effect of clonidine on sleep patterns in man.

Authors:  A Autret; M Minz; T Beillevaire; H P Cathala; H Schmitt
Journal:  Eur J Clin Pharmacol       Date:  1977-12-16       Impact factor: 2.953

9.  Centrally induced hypotension and bradycardia after administration of alpha-methylnoradrenaline into the area of the nucleus tractus solitarii of the rat.

Authors:  W De Jong; F P Nijkamp
Journal:  Br J Pharmacol       Date:  1976-12       Impact factor: 8.739

10.  Methyldopa produces central inhibition of parasympathetic activity in the cat.

Authors:  M C Koss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-11       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.